Viatris wins court decision invalidating astrazeneca's symbicort® patent

Pittsburgh , nov. 10, 2022 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced that it and kindeva drug delivery l.p. have won a significant court decision in which the u.s. district court for the northern district of west virginia found that astrazeneca's symbicort® patent, u.s. patent no.

VTRS Ratings Summary

VTRS Quant Ranking